Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$10.97
-0.11-0.99%
At close: -
$10.97
0.000.00%
After Hours: Dec 20, 4:04 PM EDT
Comments
Loading...
Immunome (NASDAQ:IMNM) Stock, Analyst Ratings, Price Targets, Forecasts
Immunome Inc has a consensus price target of $22.71 based on the ratings of 7 analysts. The high is $35 issued by Guggenheim on April 15, 2024. The low is $8 issued by Cantor Fitzgerald on March 20, 2023. The 3 most-recent analyst ratings were released by Piper Sandler, Stephens & Co., and Wedbush on November 14, 2024, November 8, 2024, and October 25, 2024, respectively. With an average price target of $28 between Piper Sandler, Stephens & Co., and Wedbush, there's an implied 155.24% upside for Immunome Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Piper Sandler
Stephens & Co.
Wedbush
JP Morgan
Guggenheim
1calculated from analyst ratings
Analyst Ratings for Immunome
Data brought to you by Benzinga APIs
FAQ
What is the target price for Immunome (IMNM) stock?
The latest price target for Immunome (NASDAQ:IMNM) was reported by Piper Sandler on November 14, 2024. The analyst firm set a price target for $21.00 expecting IMNM to rise to within 12 months (a possible 91.43% upside). 10 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Immunome (IMNM)?
The latest analyst rating for Immunome (NASDAQ:IMNM) was provided by Piper Sandler, and Immunome maintained their overweight rating.
When was the last upgrade for Immunome (IMNM)?
There is no last upgrade for Immunome
When was the last downgrade for Immunome (IMNM)?
There is no last downgrade for Immunome.
When is the next analyst rating going to be posted or updated for Immunome (IMNM)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Immunome, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Immunome was filed on November 14, 2024 so you should expect the next rating to be made available sometime around November 14, 2025.
Is the Analyst Rating Immunome (IMNM) correct?
While ratings are subjective and will change, the latest Immunome (IMNM) rating was a maintained with a price target of $23.00 to $21.00. The current price Immunome (IMNM) is trading at is $10.97, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.